Chemotaxis Induced by CMV UL146/vCXC1 and Neutralization by CMV UL146/vCXC1 Antibody. |
Recombinant Viral CMV UL146/vCXC1 (Catalog # 620-CM) chemoattracts the BaF3 mouse pro-B cell line transfected with human CXCR2 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Viral CMV UL146/vCXC1 (0.3 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti-Viral CMV UL146/vCXC1 Monoclonal Antibody (Catalog # MAB620). The ND50 is typically 1.5‑7.5 µg/mL.
Cytomegalovirus (CMV), a member of the beta herpesvirus subfamily, typically causes subclinical or latent infections in the normal adult population. However, CMV can cause congenital disease during pregnancy and is a human opportunistic pathogen that affects immunocompromised individuals. The CMV genome has been shown to contain homologs of cellular immunomodulatory proteins, including US28 (a CC chemokine receptor) and a MHC class I homolog. Virulent CMV clinical isolates have also been shown to carry at least 19 genes, designated UL133-UL151, that are not found in laboratory strains that have lost virulence characteristics. Two of these genes, UL146 and UL147, exhibit sequence similarity to CXC chemokines.
The CMV UL146 open-reading frame encodes a 117 amino acid residue precursor protein with a predicted 22 residues signal peptide that is cleaved to generate the mature protein. Recombinant UL146 has been shown to induce calcium mobilization, chemotaxis and degranulation of neutrophils.